Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

This trial is testing whether using a PET scan (a special imaging scan that highlights active tumour areas) to guide targeted radiation therapy (SBRT — stereotactic body radiation therapy) improves outcomes for people with non-small cell lung cancer (NSCLC), melanoma, or kidney cancer whose disease has progressed in a limited number of spots while on systemic therapy. **You may be eligible if...** - You are 18 years or older - You have NSCLC, melanoma, or renal cell carcinoma with 1–5 sites of disease progression while on immune checkpoint inhibitor therapy - You have received systemic therapy for at least 3 months - Your tumor sites are suitable for precision radiation (SBRT) - Your lesions are at least 1 cm in size - Your performance status (ECOG) is 0–2 - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You have more than 5 areas of active cancer progression - Your cancer sites are too close to critical structures to safely deliver radiation - You have untreated active brain metastases (brain metastases must be treated before enrolling) - Your primary tumor is not controlled Talk to your doctor to see if this trial is right for you.